143 related articles for article (PubMed ID: 16330578)
1. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Brogsitter C; Pinkert J; Bredow J; Kittner T; Kotzerke J
J Nucl Med; 2005 Dec; 46(12):2112-6. PubMed ID: 16330578
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG.
Hoefnagel CA; Taal BG; Sivro F; Boot H; Valdes Olmos RA
Nucl Med Commun; 2000 Aug; 21(8):755-61. PubMed ID: 11039459
[TBL] [Abstract][Full Text] [Related]
3. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
4. [Role of 131I-metaiodobenzylguanidine scintigraphy in the diagnosis of intestinal carcinoids].
Bihl H; Sautter-Bihl ML; Wilhelm KR; Kimmig B
Nuklearmedizin; 1987 Dec; 26(6):263-7. PubMed ID: 3438170
[TBL] [Abstract][Full Text] [Related]
5. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors.
Zagar I; Han R; Mitrovic S
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):13-6. PubMed ID: 9002742
[TBL] [Abstract][Full Text] [Related]
6. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
7. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
8. Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma.
Von Moll L; McEwan AJ; Shapiro B; Sisson JC; Gross MD; Lloyd R; Beals E; Beierwaltes WH; Thompson NW
J Nucl Med; 1987 Jun; 28(6):979-88. PubMed ID: 3035114
[TBL] [Abstract][Full Text] [Related]
9. Efficient production of therapeutic doses of [131I]-metaiodobenzylguanidine for clinical use.
Prabhakar G; Mathur A; Shunmugam G; Teje YD; Sachdev SS; Sivaprasad N
Appl Radiat Isot; 2011 Jan; 69(1):63-7. PubMed ID: 20933432
[TBL] [Abstract][Full Text] [Related]
10. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
11. [Contribution of 131I MIBG scintigraphy in the diagnosis of carcinoid tumors of the digestive tract. Experience of 14 cases].
Siproudhis L; Lescouarc'h J; Bretagne JF; Bourguet P; Raoul JL; Etienne PL; Herry JY; Gosselin M
Gastroenterol Clin Biol; 1991; 15(11):789-93. PubMed ID: 1769467
[TBL] [Abstract][Full Text] [Related]
12. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
13. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Taal BG; Hoefnagel CA; Valdes Olmos RA; Boot H; Beijnen JH
J Clin Oncol; 1996 Jun; 14(6):1829-38. PubMed ID: 8656251
[TBL] [Abstract][Full Text] [Related]
14. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
[TBL] [Abstract][Full Text] [Related]
15. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
[TBL] [Abstract][Full Text] [Related]
16. (131)I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome.
Pathirana AA; Vinjamuri S; Byrne C; Ghaneh P; Vora J; Poston GJ
Eur J Surg Oncol; 2001 Jun; 27(4):404-8. PubMed ID: 11417988
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors.
Feldman JM; Blinder RA; Lucas KJ; Coleman RE
J Nucl Med; 1986 Nov; 27(11):1691-6. PubMed ID: 3772504
[TBL] [Abstract][Full Text] [Related]
18. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit.
Hanson MW; Schneider AM; Enterline DS; Feldman JM; Gockerman JP
J Nucl Med; 1998 Apr; 39(4):647-50. PubMed ID: 9544672
[TBL] [Abstract][Full Text] [Related]
20. [131I]MIBG radionuclide therapy in carcinoid syndrome.
Taal BG; Zuetenhorst H; Valdés Olmos RA; Hoefnagel CA
Eur J Surg Oncol; 2002 Apr; 28(3):243. PubMed ID: 11944956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
